Compare CASH & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CASH | PGEN |
|---|---|---|
| Founded | 1954 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | CASH | PGEN |
|---|---|---|
| Price | $74.12 | $4.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $91.00 | $7.67 |
| AVG Volume (30 Days) | 245.8K | ★ 4.9M |
| Earning Date | 01-20-2026 | 11-13-2025 |
| Dividend Yield | ★ 0.27% | N/A |
| EPS Growth | ★ 9.29 | N/A |
| EPS | ★ 7.87 | N/A |
| Revenue | ★ $780,120,000.00 | $6,309,000.00 |
| Revenue This Year | $10.95 | $342.78 |
| Revenue Next Year | $4.75 | $478.46 |
| P/E Ratio | $9.49 | ★ N/A |
| Revenue Growth | 5.66 | ★ 59.20 |
| 52 Week Low | $64.45 | $0.69 |
| 52 Week High | $86.00 | $5.23 |
| Indicator | CASH | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 54.32 | 55.10 |
| Support Level | $72.63 | $3.64 |
| Resistance Level | $76.39 | $4.54 |
| Average True Range (ATR) | 1.83 | 0.29 |
| MACD | -0.02 | 0.08 |
| Stochastic Oscillator | 33.84 | 62.50 |
Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.